Founder, Chairman, Chief Executive Officer, and Chief Scientific Officer
Dr. Yang Liu cofounded OncoImmune and led it until its acquisition by Merck. Dr. Liu is recognized internationally for his research on immune recognition of cancer and the activation of lymphocytes, the main immune defender against cancer. He received the Markey Scholar Award in 1992, the Sears Scholar Award in 1993, and the Snyder Award for Cancer Research in 2015 and was elected to the rank of Fellow at the American Association for the Advancement of Science (AAAS) in 2004 for his pioneering contribution to innate immunity, T-cell costimulation, and cancer immunology.
Dr. Liu received his PhD from the Australian National University and completed his postdoctoral fellowship at Yale University. Prior to serving full time as Chief Executive Officer of OncoC4, he was on faculty at multiple academic institutions, including Yale University, New York University, Ohio State University, the Children’s National Medical Center, and the Institute of Human Virology at the University of Maryland School of Medicine.
Founder, Chief Medical Officer, and Board Member
Dr. Pan Zheng cofounded OncoImmune and served as Chief Medical Officer (CMO) until its acquisition by Merck. Dr. Zheng led OncoImmune’s clinical development, including the first-in-human trials in healthy volunteers and patients with cancer, as well as the successful completion of a phase 2 and phase 3 clinical trial establishing the safety and therapeutic efficacy of OncoImmune’s flagship products.
Prior to serving as OncoC4’s CMO, Dr. Zheng was on faculty in multiple academic institutions, including Ohio State University, the Children’s National Medical Center, and the Institute of Human Virology at the University of Maryland School of Medicine. She was trained in anatomic and clinical pathology and is a board-certified physician with the American Board of Pathology.
Chief Operating Officer
Dr. Helen Schiltz has more than 25 years of experience in the biotechnology industry and with the US government in the development and management of therapeutic, diagnostic, and vaccine products for a wide range of bacterial and viral biodefense and emerging infectious pathogens. As a formal program officer in the Office of Biodefense Research, Resources and Translational Research (OBRRTR) within the National Institute of Allergy and Infectious Diseases (NIAID), Dr. Schiltz was instrumental in building a successful BEI Resources Reagents and Repository Program for NIAID that supports US and international research and development efforts for diagnostic, vaccine, and therapeutic products. Furthermore, she was a founding member and acting chief of the Drug Development Section of OBRRTR and has made significant contributions to the overall strategic implementation of NIAID’s biodefense research and development agenda in building a robust therapeutic portfolio targeting a wide selection of high-priority bacterial and viral pathogens spanning from preclinical to early clinical (phase 1 and 2) development stages.
Dr. Schiltz has worked with a variety of technologies and innovative approaches for products, including biologics (recombinant protein and antibodies) and small molecules (siRNA, peptides, and other chemical entities) for inhaled, oral, and parenteral administrations. She has overseen more than 20 IND submissions and multiple clinical phase 1 and 2 trials and is a leading expert in the development of products that are licensed under the Animal Rule.
Prior to joining OncoC4 and OncoImmune, Dr. Schiltz was Senior Director of research and development at the Sabin Vaccine Institute. Before joining NIAID, she held manager and director positions for research and development at Qiagen (formally Digene) and Metrigenix, where she developed HIV, HBV, and parvovirus B19 quantitative detection assays and HPV genotyping assays, as well as multiplex genomic and proteomic arrays for disease biomarkers. Dr. Schiltz received her master of science degree from Sun Yat-Sen University in Guangzhou China and her doctoral degree in biochemistry from Louisiana State University.
Chief Financial Officer (China)
Mr. Shiniu Wei is a seasoned financial executive with decades of experience in capital markets, corporate finance, and investment strategy.
Prior to joining OncoC4, Mr. Wei most recently held an executive role as the CFO and Vice President of Investor Relations at GenScript Biotech (HK 1548), a global leader in Biotechnology and life science tools & services industry, where he successfully oversaw financial strategy and management across the conglomerate group with over $1 billion in annual revenue. In this role, he also led multiple key initiatives in fundraising across both the Hong Kong and U.S. markets.
Prior to joining GenScript, Shiniu was Executive Director of Secondary Market Investments at Fosun Insurance Group, where he managed diversified equity portfolios across the U.S. and China.
His earlier career includes serving as Senior Analyst and Co-Portfolio Manager at ISF Management, LLC, and as an Analyst at Protocol Capital Management, LLC, focusing on fundamental research and cross-sector equity investments. Shiniu holds an MBA in Finance and Economics from Baruch College, and a B.S. from Nanjing University.
General Counsel
James DeYonker is a legal, compliance, and IP executive with a 20+ year track record in the life sciences industry, encompassing corporate, commercial, intellectual property, and legal compliance. Previously, James served as the Chief Legal, Compliance, and IP Officer of EUROAPI, a Paris-based CDMO that was spun out of Sanofi Pharmaceuticals in 2022. Prior this role, he was the Chief Legal, Compliance, and IP Officer of Centrient Pharmaceuticals, a Bain Capital private equity portfolio company based in the Netherlands that focuses on the enzymatic production of antibiotics.
Earlier in his career, James was in private practice at Linklaters LLP and worked with a variety of active pharmaceutical manufacturers. He holds a bachelor of science degree in molecular biology from Emory University and a juris doctorate in law from Rutgers University. James is also a registered US patent attorney.
SVP, Head of BD
Dr. Pan Pan has a rich and diverse experience spanning over a decade in Business Development. During this period, Dr. Pan has dedicated his efforts to identifying and forging collaborations that maximize program value through innovative partnering models. His track record in establishing successful partnerships includes Kelun Biotech’s groundbreaking ADC licensing agreement with Merck, resulting in $1.4 billion in total payments. More recently, he orchestrated the Akeso-Summit partnership, securing a landmark upfront payment of $500 million and total payments of $5 billion. Dr. Pan’s prior scientific experience as a protein engineer at Arkema Inc complements his business acumen. Dr. Pan firmly believes that a solid foundation for a successful partnership lies in sound scientific and business assessments. His ability to deftly navigate both scientific and business domains is owed to his educational background. He holds a PhD in Chemical Biology from Stony Brook University, an MBA from the University of Massachusetts Amherst, and an MS & BS from the School of Pharmacy at Peking University.
SVP, Clinical Operations
Dr. Jamie Chen has worked in the pharmaceutical industry for more than 25years, with experience managing phase 1 to 4 clinical trials. Dr. Chen has served as Department Head for Warner Chilcott, now part of Allergan, for more than a decade, where she built the Clinical Data Management department from scratch. Taking advantage of her strong medical background, she transitioned to clinical science as a safety data reviewer at the compound level and eventually became Director of Medical Affairs and leading the company clinical operation team before joining OncoC4. Dr. Chen’s experience includes full clinical operation functions and participation in multiple US Food and Drug Administration (FDA) and vendor audits. She received her MD at Peking Union Medical College.
Vice President, Global Clinical Development
Dr. Sergey Efuni has extensive experience in academia, as well as in clinical practice in the therapeutic areas of immunology/allergy, oncology, cardiology, and endocrinology, among others. Dr. Efuni has managed phase 1 to 4 clinical trials in advanced solid tumors and hematologic malignancies, chronic inflammation, allergic disorders, and neurology. He has a track record of submissions/marketing approvals with the US FDA and European Medicines Agency, including mogamulizumab (POTELIGEO) for CTCL/Cezary and istradefylline (NOURIANZ) for Parkinson’s disease (2019). Dr. Efuni received the President Award in 2018 with Kyowa Kirin and was a speaker and clinical investigator for Novo Nordisk, Sanofi, and Ely Lilly.
Vice President, Clinical Development
Dr. Kazuharu Kai joined OncoC4 in February 2024 as the clinical lead for early-phase programs. He has extensive experience in industry drug development, having worked in cell therapy, cytokine therapeutics, small molecules, and immune oncology antibodies. Notably, he was part of the XPOVIO® (selinexor) supplementary NDA filing team for relapsed/refractory multiple myeloma at Karyopharm Therapeutics.
Before starting his industry career, Dr. Kai was a research faculty member at MD Anderson Cancer Center in Houston, TX, and a research instructor at Keio University in Tokyo. Prior to these appointments, he trained as a surgical oncologist at the University of Kumamoto and a regional hospital in Kumamoto, Japan, focusing on the care of patients with breast and gastrointestinal cancers.
Vice President, Quality Assurance
Karen Hughes is a performance-driven and accomplished quality assurance professional with more than 30 years of experience in the pharmaceutical, biotechnology, and medical device industry from drug discovery and development through commercialization. Karen has a wide range of knowledge in GLP, GMP, GCP, ISO, and DEA regulations and ICH guidelines. She previously worked as a Quality and Compliance Consultant at Meridian BioGroup, a Pace Life Sciences Company, and has held quality assurance positions of increasing responsibility at Synthetic Biologics, Pharmaceutics International, Inc., Emergent BioSolutions, MGI Pharma (formerly Guilford Pharmaceuticals), and Chesapeake Biological Laboratory. Karen’s areas of expertise include quality system development, implementation, maintenance, and continuous improvement, quality auditing, risk management, employee training, and quality event investigations.
Vice President, CMC Biologics
Dr. Vadim Tsvetnitsky is an experienced biotechnology professional with more than 21 years of experience developing antibodies and vaccines. Dr. Tsvetnitsky’s particular experience is in leading complex CMC development projects.
After obtaining his undergraduate degree in chemical engineering, Dr. Tsvetnitsky earned his PhD in biochemistry from the University of London School of Pharmacy. He subsequently completed postdoctoral training in protein biochemistry and molecular biology prior to directing multiple product development teams while holding positions of increased responsibility at Cangene, PATH, IAVI, and Codagenix. Dr. Tsvetnitsky has deep expertise in all aspects of CMC, preclinical development, regulatory writing, early-stage clinical trials, and technical operations.
Vice President of Finance
Sean Prestia is a strategic finance professional with extensive experience leading financial operations, corporate planning, and system transformation within the life sciences industry. Prior to joining OncoC4, Sean held finance leadership roles at Miltenyi Biotec and Hawthorne Gardening Company, where he established FP&A functions, improved operational forecasting, and supported M&A integrations totaling over $500 million. He began his career in the life sciences sector with Eppendorf North America. Sean holds an MBA in Finance from Hofstra University and a Bachelor of Science in Biochemistry from Stony Brook University. He is also a Certified Corporate FP&A Professional (FPAC).
Vice President, Clinical Development
Dr. Yao Wang has over 18 years of clinical development experience in the pharmaceutical industry. During her career, she has held positions of increasing responsibilities at both large pharmaceutical and emerging biotechnology companies, including Allergan, Kyowa Kirin, Celgene, and Amgen. She has successfully advanced clinical programs across immunology, hematology, oncology, and CNS, making significant contributions to multiple successful NDA and sNDA filings, including Otezla, Vraylar, and Nourianz. Dr. Wang received her Master of Medicine from Peking University Health Science Center (Beijing Medical University) and a Master of Science from the University of Notre Dame.
Senior Vice President, CMC (China)
Wei Zhu serves as the Senior Vice President of CMC at AcroImmune, a Chinese Subsidiary of OncoC4 and General Manager of Nanjing AcroImmune, where he oversees CMC strategy, process development, technology transfer, and manufacturing operations.
Mr. Zhu has more than 20 years of experience in biologics development and commercialization, with extensive expertise in antibody therapeutics. Throughout his career, he has led and managed multiple IND- and BLA-enabling programs and has broad experience spanning product early research, process and analytical development, and GMP manufacturing and scale-up production.
Prior to joining AcroImmune, Mr. Zhu held senior leadership roles at Shanghai Celgen Bio-Pharmaceutical and Bio-Thera Solutions, where he was responsible for antibody process development, clinical supply manufacturing, CDMO collaborations, technology transfer, and commercial production. He also spearheaded the design and construction of large-scale manufacturing facilities and managed project management operations. In 2022, he served as General Manager of Zhejiang Huahai Biotechnology before joining AcroImmune in 2023.
Mr. Zhu holds a Master’s degree in Biochemistry and Molecular Biology from Nankai University.
Senior Vice President, Operations (China)
Fenghua(Peter) Cai serves as Senior Vice President, Operations at AcroImmune (Chinese Subsidiary of OncoC4), where he oversees corporate operations, organizational infrastructure, administrative systems, and operational governance. He also serves as the company’s Legal Representative and Secretary of the Board.
Mr. Cai has over 30 years of experience in operations management, market expansion, and organizational leadership across biotechnology, consumer electronics, and petrochemical industries. Since helping establish AcroImmune in 2018, he has led the development and optimization of core operational systems, including human resources, administration, and financial management, providing essential support for the advancement of the company’s clinical-stage pipeline in oncology and autoimmune diseases.
Prior to joining AcroImmune, Mr. Cai held senior management roles at Samsung (China) Investment Co., Ltd., LG (China) Investment Co., Ltd., and Nokia (China) Investment Co., Ltd., where he was responsible for business operations, market development, and regional management. Earlier in his career, he worked at Mobil Oil (China) Investment Co., Ltd. and the Beijing Research Institute of Petrochemical Technology.
Mr. Cai holds a Bachelor of Engineering degree from China University of Petroleum.
Senior Vice President, Research & Development and Chief Research Scientist (China)
Dr. Qunmin Zhou serves as Senior Vice President, Research & Development at AcroImmune (Chinese Subsidiary of OncoC4) and Chief Research Scientist of its Nanjing entity. He is responsible for pipeline strategy, candidate nomination, and advancement of the company’s therapeutic programs.
The pipeline includes potential first-in-class and best-in-class candidates across multiple modalities, including monoclonal antibodies, bispecific and multispecific antibodies, Fc-fusion proteins, and antibody-drug conjugates, primarily in oncology and autoimmune diseases.
Prior to joining AcroImmune, Dr. Zhou co-founded a biotechnology company focused on antibody therapeutics for oncology and ophthalmology. His work has contributed to multiple IND approvals and successful proof-of-concept clinical studies.
Dr. Zhou received his medical degree from Shanghai Medical University and his Ph.D. in Molecular Oncology and Immunology from New York University School of Medicine. He completed postdoctoral training at Memorial Sloan Kettering Cancer Center.
Senior Vice President, Clinical Development and Operations (China)
Dr. Shiling Song serves as Senior Vice President, Clinical Development and Operations at AcroImmune (Chinese Subsidiary of OncoC4), where she oversees medical strategy and clinical operations in China.
She has more than 30 years of clinical medical experience, with a long-standing focus on clinical diagnosis and treatment of infectious diseases and hepatology. She is also experienced in managing clinical trials for biologics. Prior joining the company in 2021, She has worked for many years at a top-tier (Class III, Grade A) public hospitals in China, serving as Director of the Infectious Diseases Department, and held the professional title of Chief Physician.
At AcroImmune, Dr. Song manages China-based clinical trials across oncology programs and studies involving healthy subjects, providing medical oversight and operational leadership to support clinical development.
Dr. Song received her medical degree from Wuhan University.
Vice President, Regulatory Affairs (China)
Dr. Dongling Li serves as Vice President, Regulatory Affairs (China) at AcroImmune (Chinese Subsidiary of OncoC4), where she leads regulatory strategy and execution for drug development programs in China.
Since joining the company in 2017, she has played a key role in establishing the China regulatory framework and advancing the company’s pipeline. Under her leadership, the team has secured multiple IND approvals for Class 1 new drugs, approvals for CMC supplemental applications, and one Breakthrough Therapy Designation in China. She has also led numerous formal communications with the Center for Drug Evaluation (CDE).
Before Joining the company, Dr. Li was an Associate Research Fellow at the Institute of Biophysics, Chinese Academy of Sciences, where she dedicated her work to study the molecular mechanisms of CD24 in liver cancer and autoimmune diseases. She also conducted research as a visiting scholar at the University of Michigan Medical Center.
Dr. Li holds a Ph.D. in Biochemistry and Molecular Biology from Peking University.
Founder, Chairman, Chief Executive Officer, and Chief Scientific Officer
Dr. Yang Liu cofounded OncoImmune and led it until its acquisition by Merck. Dr. Liu is recognized internationally for his research on immune recognition of cancer and the activation of lymphocytes, the main immune defender against cancer. He received the Markey Scholar Award in 1992, the Sears Scholar Award in 1993, and the Snyder Award for Cancer Research in 2015 and was elected to the rank of Fellow at the American Association for the Advancement of Science (AAAS) in 2004 for his pioneering contribution to innate immunity, T-cell costimulation, and cancer immunology.
Dr. Liu received his PhD from the Australian National University and completed his postdoctoral fellowship at Yale University. Prior to serving full time as Chief Executive Officer of OncoC4, he was on faculty at multiple academic institutions, including Yale University, New York University, Ohio State University, the Children’s National Medical Center, and the Institute of Human Virology at the University of Maryland School of Medicine.
Founder, Chief Medical Officer, and Board Member
Dr. Pan Zheng cofounded OncoImmune and served as Chief Medical Officer (CMO) until its acquisition by Merck. Dr. Zheng led OncoImmune’s clinical development, including the first-in-human trials in healthy volunteers and patients with cancer, as well as the successful completion of a phase 2 and phase 3 clinical trial establishing the safety and therapeutic efficacy of OncoImmune’s flagship products.
Prior to serving as OncoC4’s CMO, Dr. Zheng was on faculty in multiple academic institutions, including Ohio State University, the Children’s National Medical Center, and the Institute of Human Virology at the University of Maryland School of Medicine. She was trained in anatomic and clinical pathology and is a board-certified physician with the American Board of Pathology.
Board Member
Dr. Kun-Liang Guan is an authority on signal transduction in cell growth regulation, organ size control, and tumorigenesis. Dr. Guan demonstrated the role of tuberous sclerosis tumor suppressors in cell growth by inhibiting mechanistic target of rapamycin (mTOR) and contributed to the establishment of the mTOR signaling network. He discovered the signals and receptors for the elusive Hippo/YAP pathway and revealed the biochemical mechanism of its regulation. Dr. Guan was elected Fellow of the AAAS in 2008 for his pioneering contribution to cell biology and signal transduction.
Dr. Guan earned his bachelor degree from Hangzhou University and PhD from Purdue University. He won the Young Investigator Award from the American Society for Biochemistry and Molecular Biology, the MacArthur Fellow from the MacArthur Foundation, and the Distinguished Alumni Award from Purdue University. Dr. Guan is a highly cited researcher in molecular biology and genetics (Thomson Reuter).
Advisory Board Member
Dr. Michael Caligiuri (pronounced KALAJURY) is President of the City of Hope National Medical Center in Los Angeles, California. Dr. Caligiuri is also the Deana and Steve Campbell Physician-in-Chief Distinguished Chair.
Prior to his appointment at City of Hope in 2018, Dr. Caligiuri was the Chief Executive Officer (CEO) of the Ohio State University (OSU) James Cancer Hospital (2008 to 2017) and Director of OSU’s Comprehensive Cancer Center (CCC; 2003 to 2017); he served as the Director of OSU’s Division of Hematology-Oncology from 2000 through 2008. While Director of the CCC and CEO of OSU hospital, Dr. Caligiuri oversaw the construction of the third largest cancer hospital in the US and recruited more than 300 physicians and scientists to OSU.
Dr. Caligiuri is a physician–scientist whose basic and translational work has focused on immunotherapy for both liquid and solid tumors. His laboratory has studied human natural killer (NK) cells for 35 years and has produced more than 400 original peer-reviewed publications on NK cells and/or cancer. Pivotal discoveries from the Caligiuri laboratory have made it possible to bring chimeric antigen receptor (CAR) NK cells from the laboratory into the clinic for cancer therapy. These include proprietary retroviral transduction of human NK cells, the elucidation of the site, stages, cytokines, and molecular mechanisms involved in the differentiation of human NK cells from CD34(+) hematopoietic stem cells, and the discovery of IL-15 as the key cytokine for human NK-cell development, survival, growth, and activation. These 3 discoveries alone have been critical for the genesis of CAR NK cells from peripheral blood, umbilical cord blood, and induced pluripotent stem cells. Most of this work was accomplished with his collaborator, Jianhua Yu, PhD.
Dr. Caligiuri has designed and conducted clinical studies modulating NK cells for more than 1000 patients with cancer. More than 100 students have trained in the Caligiuri laboratory and have received more than 200 local, state, national, and international awards for their research.
Dr. Caligiuri is an elected member of the American Society for Clinical Investigation and the Association of American Physicians, and he is an elected Fellow of the AAAS. He is past president of the Association of American Cancer Institutes and past president of the Society for Natural Immunity and most recently served as President of the American Association for Cancer Research (AACR), the world’s largest cancer research organization. Dr. Caligiuri has served on the National Cancer Institute (NCI) Board of Scientific Counselors and Board of Scientific Advisors; he was chairman of the Institute of Medicine’s National Cancer Policy Forum from 2014 to 2016. In 2010, Dr. Caligiuri was one of 4 individuals in the country to receive a MERIT award from the NCI for his work on immunity and cancer, and in 2016, he received an Outstanding Investigator Award from the NCI. In 2018, he received the lifetime achievement award from the Stanford University School of Medicine and was elected Fellow of the AACR Academy and a member of the USA National Academy of Medicine.
Dr. Caligiuri is cofounder of Pelotonia (www.pelotonia.org), the Oncology Research Information Exchange Network (www.ORIENcancer.org), CancerBridge (www.mycancerbridge.com), the Ohio State University Drug Development Institute (https://cancer.osu.edu/research-and-education/drug-development-institute), and CytoImmune Therapeutics (www.cytoImmune.com).
Dr. Caligiuri earned his undergraduate degree from the State University of New York at Buffalo and his masters and medical degrees from the Stanford University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital at Harvard Medical School in Boston, MA, then completed a fellowship in medical oncology, bone marrow transplantation, and immunology at the Dana-Farber Cancer Institute at Harvard Medical School. Dr. Caligiuri then spent 7 years at Roswell Park Cancer Institute as an assistant, associate, and full professor before moving to Ohio State University in 1997 and City of Hope in 2018.
Complete list of Dr. Caligiuri’s published work:
https://www.ncbi.nlm.nih.gov/pubmed/?term=caligiuri+ma
Advisory Board Member
Dr. Lieping Chen is a United Technologies Corporation Professor in Cancer Research, Professor of Immunobiology, Medicine (Medical Oncology), and Dermatology, and Co-Leader, Cancer Immunology Program at Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut. Prior to joining Yale, Dr. Chen was a faculty member at Johns Hopkins and the Mayo Clinic and also a scientist at the Bristol Myers Squibb Company. His laboratory studies the cell-surface proteins that control lymphocyte function, and he also translates his laboratory findings for treating human diseases including cancer.
Dr. Chen did the first proof-of-concept study in 1992 demonstrating that the B7-CD28 family molecules could be the targets for cancer immunotherapy by introducing B7-1 into tumor cells to enhance therapeutic immunity. In 1999, he discovered the B7-H1 (also called PD-L1) molecule and subsequently demonstrated the role of PD-L1 in the evasion of tumor immunity and established the PD-1/PD-L1 pathway as the target for cancer immunotherapy. Dr. Chen also initiated and helped organize the first-in-human clinical trial of an anti–PD-1 antibody for treating cancer and developed PD-L1 detection as a biomarker to predict therapeutic outcomes. These discoveries directly led to the development of anti–PD-1/PD-L1 antibody therapy for a broad spectrum of human cancers. His laboratory also discovered many molecular pathways with immune modulatory functions, as well as their applications in disease treatment. These discoveries led to the development of therapeutic agents in various stages of clinical trials for the treatment of cancer.
In recognition of his scientific achievements, Dr. Chen has been awarded several honors, including the William B. Coley Award in 2014, the AAI-Steinman Award in 2016, the Warren Alpert Foundation Prize in 2017, the Giants of Cancer Care award in 2018, and the Richard V. Smalley Award in 2020. He is a member of the National Academy of Sciences and a Fellow of the AACR Academy.
Advisory Board Member
Dr. Kun-Liang Guan is a Distinguished Professor of Pharmacology at the University of California, San Diego. Dr. Guan received his BS from Hangzhou University and his PhD from Purdue University. He was a faculty member at the University of Michigan from 1992 to 2007. Dr. Guan received the MacArthur Fellowship in 1998, the American Society of Biochemistry and Molecular Biology Young Investigator Award in 1999, the Distinguished Alumni Award from Purdue University in 2006, and an AAAS fellowship in 2011.
Dr. Guan’s research interest is in cellular signaling and cancer biology, particularly on protein phosphorylation in cell-growth regulation and tumorigenesis. He has worked on the mitogen-activated protein kinase (MAPK), mTOR, and Hippo pathways. Dr. Guan has authored more than 300 peer-reviewed publications and is a highly cited researcher in molecular biology and genetics (Goggle Scholar H-index 150). He is a cofounder of OncoImmune Inc. and Vivace Therapeutics.
Complete list of Dr. Guan’s published work: https://pubmed.ncbi.nlm.nih.gov/?term=Guan+kl
Advisory Board Member
Dr. Kun He is the Chief Statistician of R&G US Inc. Dr. He provides regulatory, clinical, and statistical sciences consulting to pharmaceutical and biotechnology companies, serves on the independent Data Monitoring Committee for global trials, and participates in developing regulatory guidance for the Center for Drug Evaluation of the National Medical Products Administration. Before joining R&G in 2019, he worked at the Center for Drug Evaluation and Research at the US FDA for 20 years, most recently serving as Associate Division Director of the Division of Biometrics V, supporting the Office of Hematology and Oncology Products. During his FDA tenure, Dr. He reviewed thousands of INDs, including I-SPY2, Lung-Map, and GBM Agile, as well as hundreds of NDAs/BLAs, including the initial approvals of YERVOY, KEYTRUDA, OPDIVO, BAVENCIO, and LIBTAYO. Prior to joining the FDA in 1999, he served on the faculties of the University of Kansas and the University of Minnesota.
Dr. He received a BS in mathematics from the University of Science and Technology of China, an MS in statistics from Peking University, and a PhD in statistics from Cornell University.
Advisory Board Member
Heather A. Wakelee, MD, FASCO brings over 20 years of clinical experience specializing in the treatment of lung cancer, thymoma, and mesothelioma. Currently she serves as Deputy Director of the Stanford Cancer Institute and is the Division Chief of Medical Oncology. She is the President of the International Association for the Study of Lung Cancer (IASLC) and is active in several national and international organizations related to lung cancer and thymoma. Previously as physician lead for the thoracic malignancies clinical research group at Standford, she developed research programs related to lung cancer and thymoma across clinical trials, translation work and population sciences. She is the Principal Investigator on numerous clinical trials and has held advisory board roles with Genentech/Roche, Janssen, Daiichi Sankyo, and Mirati. Dr. Wakelee is a board-certified physician in internal medicine and medical oncology. She completed a fellowship in oncology and a residency in internal medicine at Stanford University. She holds a medical degree from Johns Hopkins University, and a Bachelor of Arts from Princeton University in Molecular Biology.
Advisory Board Member
Jeffrey Cummings, MD, ScD(HC), is the Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Gundy Center for Transformative Neuroscience, and Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). Dr. Cummings is a Neurologist and is globally recognized for his contributions to Alzheimer’s research, drug development, and clinical trials. He leads the UNLV Clinical Trials Observatory that studies all drugs in current clinical trials for Alzheimer’s disease to better inform drug development decisions. Dr. Cummings has been honored with through the Henderson Award of the American Geriatrics Society, Distinguished Scientist Award of the American Association of Geriatric Psychiatry, Leadership and Achievement Award by the International Society of CNS Drug Development, the Bengt Winblad Lifetime Achievement Award from the national Alzheimer’s Association. International Psychogeriatric Association Distinguished Service Award, and the Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize for Excellence in Drug Development. Dr. Cummings is a Fellow to the American Academy for the Advancement of Science. Dr. Cummings was the founding director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA and founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health. He is completed training in Neurology (Boston University) and Behavioral Neurology (Boston University) with additional training in Neuropsychiatry and Neuropathology (National Hospital for Nervous Diseases, Queen Square, London). Dr. Cummings has published 43 books and over 900 peer-reviewed papers on Alzheimer’s disease, neuropsychiatry, and clinical trials.
